[ccpw id="5"]

Home.forex news reportTruist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After...

Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback

-


Boston Scientific Corporation (NYSE:BSX) is included among 13 Best Long Term Low Risk Stocks to Buy Now.

Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback
Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback

On February 5, Truist lowered its price objective on Boston Scientific Corporation (NYSE:BSX) to $95 from $120. The firm maintained a Buy rating on the stock. In a note to clients, the analyst said the sharp pullback after earnings appeared excessive, especially with the stock now trading at a discount to faster-growing peers.

The reaction followed the company’s February 4 earnings release, which highlighted weaker-than-expected results in the electrophysiology business. That unit, which focuses on minimally invasive treatments for heart rhythm disorders, is a key part of Boston Scientific’s growth narrative. Fourth-quarter sales in the segment reached $890 million, falling short of the $933 million analysts had been expecting, according to RBC Capital Markets. The miss unsettled investors, who questioned whether growth in the segment was losing momentum. Citi analyst Joanne Wuensch said those worries were justified.

Sales of the Watchman device, used to help prevent strokes in patients with atrial fibrillation, also came in about 1% below forecasts. Analysts attributed the shortfall mainly to softer demand in the US market. For the year ahead, Boston Scientific forecasts adjusted earnings per share of $3.43 to $3.49. The midpoint of that range landed just under Wall Street expectations of $3.47, based on data from LSEG. On the quarter, revenue totaled $5.29 billion and adjusted earnings were 80¢ per share, both roughly in line with estimates.

Looking further out, the company expects organic revenue growth of 10% to 11% in 2026, pointing to a slower pace compared with the 15.8% organic growth reported in 2025.

Boston Scientific Corporation (NYSE:BSX) develops and sells medical devices used across a wide range of interventional procedures around the world.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Best Wide Moat Dividend Stocks to Invest in and 12 Best HVAC Stocks to Buy Now

Disclosure: None.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

LATEST POSTS

Why This Power Play Could Ride the AI Data Center Boom Higher

Artificial intelligence continues to take off, and hyperscalers are spending boatloads of money over the next several years to build out...

Italian olive oil farmers say flood of imports is causing price collapse

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.Italian olive oil producers say a...

Bitcoin crash sends shock to 401(k) investors

“Sometimes we look at things that we say, ‘you know what, we should get out,’ and sometimes we don't. And last...

Walmart surprises shoppers with bold new restaurant offering

Walking into Walmart used to mean being hit with the distinctive smell of McDonald's food cooking. For some, that's a comforting...

Follow us

0FansLike
0FollowersFollow
0SubscribersSubscribe

Most Popular

spot_img